Find verified Sacubitril valsartan sodium hydrate API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Sacubitril valsartan sodium hydrate for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Sacubitril valsartan sodium hydrate API.
Alternate Names: Entresto, VALSARTAN AHU-377 SODIUM HEMIPENTAHYDRATE
CAS No: 936623-90-4
PubChem CID: 71449007
Mol Formula: C96H120N12Na6O21
Mol Weight: 1916.0 g/mol
IUPAC Name: hexasodium;bis(4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate);bis((2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3 -Show More
API Description: Sacubitril/Valsartan is a combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.
